- Home
- GLU vs CNTB Comparison
GLU vs CNTB Comparison
Compare GLU & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLU
- CNTB
- Stock Information
- Founded
- GLU 2004
- CNTB 2012
- Country
- GLU United States
- CNTB United States
- Employees
- GLU N/A
- CNTB N/A
- Industry
- GLU Finance/Investors Services
- CNTB Biotechnology: Pharmaceutical Preparations
- Sector
- GLU Finance
- CNTB Health Care
- Exchange
- GLU Nasdaq
- CNTB Nasdaq
- Market Cap
- GLU 99.4M
- CNTB 54.4M
- IPO Year
- GLU N/A
- CNTB 2021
- Fundamental
- Price
- GLU $17.59
- CNTB $1.46
- Analyst Decision
- GLU
- CNTB Strong Buy
- Analyst Count
- GLU 0
- CNTB 2
- Target Price
- GLU N/A
- CNTB $7.50
- AVG Volume (30 Days)
- GLU 12.4K
- CNTB 148.9K
- Earning Date
- GLU 01-01-0001
- CNTB 09-04-2025
- Dividend Yield
- GLU 8.60%
- CNTB N/A
- EPS Growth
- GLU N/A
- CNTB N/A
- EPS
- GLU 0.62
- CNTB N/A
- Revenue
- GLU N/A
- CNTB $26,033,000.00
- Revenue This Year
- GLU N/A
- CNTB N/A
- Revenue Next Year
- GLU N/A
- CNTB N/A
- P/E Ratio
- GLU $22.50
- CNTB N/A
- Revenue Growth
- GLU N/A
- CNTB N/A
- 52 Week Low
- GLU $11.61
- CNTB $0.51
- 52 Week High
- GLU $15.40
- CNTB $1.60
- Technical
- Relative Strength Index (RSI)
- GLU 63.14
- CNTB 72.56
- Support Level
- GLU $17.50
- CNTB $1.05
- Resistance Level
- GLU $17.70
- CNTB $1.56
- Average True Range (ATR)
- GLU 0.19
- CNTB 0.13
- MACD
- GLU 0.01
- CNTB 0.04
- Stochastic Oscillator
- GLU 74.70
- CNTB 84.59
About GLU Gabelli Global Utility of Beneficial Ownership
Gabelli Global Utility & Income Trust is a non-diversified, closed-end management investment company. The Fund's objective is to seek a consistent level of after-tax total return. It predominantly invests in stocks of companies involved to a substantial extent in providing products, services, or equipment for the generation or distribution of electricity, gas, or water and infrastructure operations, and in equity securities including preferred securities of companies in other industries, in each case in such securities that are expected to pay periodic dividends.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.